ClinicalTrials.gg
CompletedNCT03098797TAZPOWERUpdated Apr 16, 2024Results posted

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

A Phase 2/3 interventional study of Elamipretide and Placebo in Barth Syndrome, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
12 Years and older
Sex
Male
01

Study summary

A randomized, double-blind cross over trial to evaluate the safety, efficacy, and tolerability of elamipretide in subjects with Barth syndrome.

Read the detailed description

A phase 2 randomized, double-blind, placebo-controlled crossover trial to evaluate the safety, tolerability, and efficacy of subcutaneous injections of elamipretide in subjects with genetically confirmed Barth syndrome followed by open-label treatment extension. Part 1 was a randomized, double-blind, placebo-controlled, crossover trial to assess safety, tolerability, and efficacy single daily subcutaneous (SC) doses of 40 mg elamipretide administered for 12 weeks in subjects with Barth syndrome. Part 2: This was an open-label extension trial to assess the long-term safety, tolerability, and longitudinal trends in efficacy single daily SC doses of 40 mg elamipretide for up to 192 weeks.

02

Conditions studied

  • Barth Syndrome

Keywords

  • Barth Syndrome
  • elamipretide
  • MTP-131
  • Stealth
  • Stealth BT
  • BTHS
03

In context

Lead sponsor

Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetically confirmed Barth Syndrome
  • Male aged 12 and above
  • At the screening visit, must meet the following:

    1. Body weight >30 kg AND eGFR ≥ 90mL/min at screening
    2. Body weight >40kg AND eGFR ≥60 but \<90mL/min/ 1.73m² at screening
  • Ambulatory and impaired during the baseline 6MWT
  • On stable medication for 30 days prior to the baseline visit

Exclusion criteria

Exclusion Criteria:

  • Participated in another interventional clinical trial within 30 days of or is currently enrolled in a non-interventional clinical trial at the baseline visit potentially confounding with this trial
  • Prior or current medical condition that would prevent the subject from safely participating in the trial
  • Undergone any inpatient hospitalizations within 30 days of the baseline visit
  • Is undergoing an apparent pubertal growth spurt
  • Has uncontrolled hypertension
  • History of substance abused within the year before the baseline visit or is likely to be uncompliant
  • History of heart transplantation or current placement on the waiting list for a heart transplant
  • For subjects with an ICD: known occurrence of ICD discharge in the 3 months prior to the baseline visit
  • For subjects without an ICD: expected to undergo an implantation of an ICD during the conduct of the study
  • Currently receiving treatment with chemotherapeutic agents or agents or has received prior radiation therapy to the chest
  • Recipient of stem cell or gene therapy or is currently being treated by a therapeutic device
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Elamipretide, then Placebo

    Experimental Part 1: 12 weeks of single daily SC doses of 40 mg elamipretide in Treatment Period 1 followed by 12 weeks of treatment with placebo in Treatment Period 2 (separated by a 4 week washout period). Experimental Open Label Extension Part 2: All subjects will receive Elamipretide 40mg SC daily injections for up to 168 weeks

    Drug: Elamipretide · Drug: Placebo

  • Placebo comparator
    Placebo , then Elamipretide

    Placebo Comparator Part 1: 12 weeks of single daily SC doses of placebo in Treatment Period 1 followed by 12 weeks of treatment with 40 mg elamipretide in Treatment Period 2 (separated by a 4 week washout period). Placebo Comparator Open Label Extension Part 2: All subjects will receive Elamipretide 40mg SC daily injections for up to 168 weeks

    Drug: Elamipretide · Drug: Placebo

Interventions

  • 40 mg daily subcutaneous injection for 12 weeks

    Also known as: MTP-131

  • DrugPlacebo

    daily subcutaneous injection for 12 weeks

    Also known as: Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Part 1: Distance Walked During the 6-Minute Walk Test (6MWT) by Visit

    Average distance walked in meters during the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

    Time frame: Pre-dose to Week 12 (end of treatment)

  2. Part 1: Total Fatigue Score Based on the BTHS-SA by Visit.

    Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit at predose, Weeks 1, 4, 8, and 12 (end of treatment). The BTHS-SA is 3-question fatigue assessment using a 0 to 4-point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects; a lower score means better outcome, higher score means a worse outcome. Combined Min score=0, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Results from each 12-week period were combined, where end of treatment for Period 1 =Visit 5 (week 12), and End of Period 2 = Visit 10 (week 12)

    Time frame: Pre-dose, Weeks 1, 4, 8, and 12 (end of treatment)

Secondary outcomes

  1. Part 2: Distance Walked During the 6MWT

    Change from baseline for distance walked in meters during the 6-minute walk test (6MWT) by visit where Baseline= Part 1 Period 1 Pre-dose

    Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 168, 192

  2. Part 2: Change From Baseline: Total Fatigue Score (Q1, Q2, and Q4) Based on the BTHS-SA by Visit

    Change from Baseline (mean) in Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit. The BTHS-SA is 3-question fatigue assessment using a 0-4 point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects by visit; a lower score means better outcome, higher score means a worse outcome. Change from baseline: an increase in scores would mean worse outcome, a decrease in scores means better outcome. Combined Min score=-12, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Baseline= Period 1 Predose.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192

  3. Part 1: Muscle Strength as Measured by HHD by Visit

    Muscle strength as measured by handheld dynamometry (HHD) in Newtons, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Handheld dynamometry assesses the average strength of the knee extensors of both legs.

    Time frame: Pre-dose to Week 12 (end of treatment)

  4. Part 2: Change From Baseline: Muscle Strength by HHD (Newtons) by Visit

    Muscle strength as measured by handheld dynamometry (HHD) in Newtons. Handheld dynamometry assesses the average strength of the knee extensors of both legs. Change from baseline where Baseline= Part 1 Period 1 Pre-dose: the greater positive change, the better the outcome, the smaller positive change (or negative change) the number the worse the outcome.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96,168, 192

  5. Part 1: 5XSST by Visit

    Time (in seconds) to complete the Five Times Sit-To-Stand, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

    Time frame: Pre-dose to Week 12 (end of treatment)

  6. Part 2: Change From Baseline: 5X Sit to Stand by Visit

    Change in baseline in time (in seconds), where Baseline= Part 1 Period 1 Pre-dose to complete the Five Times Sit-To-Stand by visit. More time means worse outcome, less time means better outcome.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 168, 192

  7. Part 1: SWAY Application Balance Assessments by Visit

    SWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability from Pre-dose to Week 12 (end of treatment), where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

    Time frame: Pre-dose to Week 12 (end of treatment)

  8. Part 2: Change From Baseline: SWAY Application Balance Assessment

    Change from Baseline: SWAY Application Balance Assessment,where Baseline= Part 1 Period 1 Pre-doseSWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability. An increase from baseline is a better outcome and a decrease in score is a worse outcome.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96,168, 192

  9. Part 1: Patient Global Impression Scales of Symptoms

    Patient-reported health status over the past week, by visit, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very Severe. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.

    Time frame: Pre-dose, Week 1, Week 12 (end of treatment)

  10. Part 2: Change From Baseline: Patient Global Impression Scales of Symptoms by Visit

    Part 2: Change from Baseline: Patient Global Impression Scales of Symptoms by Visit Patient-reported health status over the past week where Baseline= Part 1 Period 1 Pre-dose, administered at Week 12 for Period 1 and Period 2. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe. Change from baseline: Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192

  11. Part 1: Part 1: Clinician Global Impression

    Clinician Global Impression Scale by visit: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome. End of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

    Time frame: Pre-dose to Week 12 (end of treatment)

  12. Part 2: Change From Baseline: CGI Symptom Scale

    Change from Baseline: CGI Symptom Scale by visit where Baseline= Part 1 Period 1 Pre-dose. Clinician Global Impression Scale: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Change from baseline: higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192

07

Results

Posted Apr 16, 2024

Participant flow

First Intervention (12 Weeks)
Participant flow — First Intervention (12 Weeks)
MilestoneExperimental: Elamipretide, Then PlaceboPlacebo, Then Elamipretide
Started66
Completed66
Not completed00
Washout (4 Weeks)
Participant flow — Washout (4 Weeks)
MilestoneExperimental: Elamipretide, Then PlaceboPlacebo, Then Elamipretide
Started66
Completed66
Not completed00
Second Intervention (12 Weeks)
Participant flow — Second Intervention (12 Weeks)
MilestoneExperimental: Elamipretide, Then PlaceboPlacebo, Then Elamipretide
Started66
Completed66
Not completed00
Part 2 Open Label Extension
Participant flow — Part 2 Open Label Extension
MilestoneExperimental: Elamipretide, Then PlaceboPlacebo, Then Elamipretide
Started55
Week 1255
Week 3635
Week 16835
Completed35
Not completed20
Withdrew: Adverse event20

Outcome measures

PrimaryPart 1: Distance Walked During the 6-Minute Walk Test (6MWT) by Visit

Average distance walked in meters during the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

Time frame:
Pre-dose to Week 12 (end of treatment)
Reported as:
Mean · meters
Part 1: Distance Walked During the 6-Minute Walk Test (6MWT) by Visit
metersExperimental: ElamipretidePlacebo
Pre-dose400.1 ± 55.07412.6 ± 60.16
Week 12 (End of Treatment443.1 ± 65.43443.9 ± 77.10
PrimaryPart 1: Total Fatigue Score Based on the BTHS-SA by Visit.

Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit at predose, Weeks 1, 4, 8, and 12 (end of treatment). The BTHS-SA is 3-question fatigue assessment using a 0 to 4-point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects; a lower score means better outcome, higher score means a worse outcome. Combined Min score=0, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Results from each 12-week period were combined, where end of treatment for Period 1 =Visit 5 (week 12), and End of Period 2 = Visit 10 (week 12)

Time frame:
Pre-dose, Weeks 1, 4, 8, and 12 (end of treatment)
Reported as:
Mean · score on a scale
Part 1: Total Fatigue Score Based on the BTHS-SA by Visit.
score on a scaleExperimental: ElamipretidePlacebo
Pre-dose7.672 ± 1.93607.433 ± 1.3848
Week 16.837 ± 2.11146.994 ± 1.7093
Week 46.220 ± 2.33256.485 ± 1.4447
Week 86.089 ± 1.83446.196 ± 1.7815
Week 126.305 ± 2.06126.240 ± 1.6384
SecondaryPart 2: Distance Walked During the 6MWT

Change from baseline for distance walked in meters during the 6-minute walk test (6MWT) by visit where Baseline= Part 1 Period 1 Pre-dose

Time frame:
Baseline to Weeks 12, 24, 36, 48, 72, 96, 168, 192
Reported as:
Mean · meters
Part 2: Distance Walked During the 6MWT
metersPart 1: Elamipretide (Sequence AB)Part 2: Placebo (Sequence BA)
Part 2: Week 1245.4 ± 55.7375.6 ± 87.25
Part 2: Week 2479.8 ± 23.54100.4 ± 94.61
Part 2: Week 3668.0 ± 31.19112.6 ± 119.35
Part 2: Week 4887.3 ± 25.58103.4 ± 102.02
Part 2: Week 72121.7 ± 20.7497.8 ± 117.53
Part 2: Week 96128.063.7 ± 69.14
Part 2: Week 16889.3 ± 32.75100.2 ± 78.10
Part 2: Week 192118.0125.0 ± 28.28
SecondaryPart 2: Change From Baseline: Total Fatigue Score (Q1, Q2, and Q4) Based on the BTHS-SA by Visit

Change from Baseline (mean) in Total Fatigue Score (Q1, Q2, and Q4) Based on the BarTH Syndrome Symptom Assessment (BTHS-SA) by visit. The BTHS-SA is 3-question fatigue assessment using a 0-4 point scale for each question where no fatigue =0 and very severe fatigue =4, with scores from all 3 questions combined and averaged for all subjects by visit; a lower score means better outcome, higher score means a worse outcome. Change from baseline: an increase in scores would mean worse outcome, a decrease in scores means better outcome. Combined Min score=-12, max score =12. Weekly values are based on the weekly average of the last 7 days before the site or visiting nurse visit for both periods. Baseline= Period 1 Predose.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192
Reported as:
Mean · score on a scale
Part 2: Change From Baseline: Total Fatigue Score (Q1, Q2, and Q4) Based on the BTHS-SA by Visit
score on a scalePart 2: OLE: (Treatment AB)Part 2: OLE: (Treatment BA)
Baseline-2.425 ± 2.0849-1.540 ± 1.3653
Week 12-1.800 ± 2.4838-1.314 ± 1.4237
Week 24-1.500 ± 2.0253-0.314 ± 1.0816
Week 36-2.667 ± 3.6821-1.714 ± 1.0583
Week 48-1.000 ± 2.9172-0.314 ± 1.0650
Week 72-2.667 ± 3.4827-1.114 ± 1.1301
Week 96-3.500 ± 2.5254-0.357 ± 1.5763
Week 120-3.000 ± 2.9172-0.114 ± 1.0309
Week 144-2.667 ± 2.2961-0.314 ± 2.0067
Week 168-2.333 ± 4.0515-0.514 ± 0.7309
Week 192-5.286-1.107 ± 0.5556
SecondaryPart 1: Muscle Strength as Measured by HHD by Visit

Muscle strength as measured by handheld dynamometry (HHD) in Newtons, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Handheld dynamometry assesses the average strength of the knee extensors of both legs.

Time frame:
Pre-dose to Week 12 (end of treatment)
Reported as:
Mean · Newtons
Part 1: Muscle Strength as Measured by HHD by Visit
NewtonsExperimental: ElamipretidePlacebo
Pre-dose131.236 ± 29.9004123.100 ± 24.6762
Week 12135.934 ± 52.2796129.253 ± 34.2395
SecondaryPart 2: Change From Baseline: Muscle Strength by HHD (Newtons) by Visit

Muscle strength as measured by handheld dynamometry (HHD) in Newtons. Handheld dynamometry assesses the average strength of the knee extensors of both legs. Change from baseline where Baseline= Part 1 Period 1 Pre-dose: the greater positive change, the better the outcome, the smaller positive change (or negative change) the number the worse the outcome.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 72, 96,168, 192
Reported as:
Mean · Newtons
Part 2: Change From Baseline: Muscle Strength by HHD (Newtons) by Visit
NewtonsPart 2: OLE: (Treatment AB)Part 2: OLE: (Treatment BA)
Week 1233.606 ± 24.730442.147 ± 34.9498
Week 2454.073 ± 29.769954.068 ± 37.3060
Week 3668.798 ± 22.889248.351 ± 31.1331
Week 4869.613 ± 20.878845.704 ± 56.8895
Week 7262.089 ± 33.475332.071 ± 31.7087
Week 9693.74538.848 ± 18.1422
Week 16857.751 ± 17.750961.897 ± 19.1573
Week 19242.36832.140 ± 17.9287
SecondaryPart 1: 5XSST by Visit

Time (in seconds) to complete the Five Times Sit-To-Stand, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

Time frame:
Pre-dose to Week 12 (end of treatment)
Reported as:
Mean · seconds
Part 1: 5XSST by Visit
secondsExperimental: ElamipretidePlacebo
Pre-dose12.965 ± 3.336613.710 ± 5.3088
Week 1214.023 ± 5.450813.749 ± 6.1024
SecondaryPart 2: Change From Baseline: 5X Sit to Stand by Visit

Change in baseline in time (in seconds), where Baseline= Part 1 Period 1 Pre-dose to complete the Five Times Sit-To-Stand by visit. More time means worse outcome, less time means better outcome.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 72, 96, 168, 192
Reported as:
Mean · seconds
Part 2: Change From Baseline: 5X Sit to Stand by Visit
secondsPart 2: OLE: (Sequence AB)Part 2: OLE: (Sequence BA)
End of Part 1-0.773 ± 2.53230.400 ± 2.7824
Week 12-1.505 ± 2.18430.384 ± 3.7167
Week 24-2.533 ± 2.7507-1.160 ± 2.8668
Week 36-3.700 ± 3.7649-0.344 ± 2.7035
Week 48-4.780 ± 2.9820-0.082 ± 2.6625
Week 72-4.770 ± 3.2043-0.454 ± 1.6369
Week 96-8.060-0.397 ± 3.6036
Week 168-4.320 ± 4.0307-0.986 ± 2.1857
Week 192-6.850-0.390 ± 1.5839
SecondaryPart 1: SWAY Application Balance Assessments by Visit

SWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability from Pre-dose to Week 12 (end of treatment), where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

Time frame:
Pre-dose to Week 12 (end of treatment)
Reported as:
Mean · Score on a scale
Part 1: SWAY Application Balance Assessments by Visit
Score on a scaleExperimental: ElamipretidePlacebo
Pre-dose70.752 ± 19.719968.820 ± 24.7478
Week 1278.698 ± 15.155471.353 ± 20.2515
SecondaryPart 2: Change From Baseline: SWAY Application Balance Assessment

Change from Baseline: SWAY Application Balance Assessment,where Baseline= Part 1 Period 1 Pre-doseSWAY application balance assessment consists of five stances each performed for 10 seconds and scores postural stability on a scale from 0-100 with higher scores indicating better postural stability. An increase from baseline is a better outcome and a decrease in score is a worse outcome.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 72, 96,168, 192
Reported as:
Mean · score on a scale
Part 2: Change From Baseline: SWAY Application Balance Assessment
score on a scalePart 2: OLE: (Sequence AB)Part 2: OLE: (Sequence BA)
Week 12-3.152 ± 29.841910.464 ± 19.1971
Week 2412.190 ± 9.67996.664 ± 9.5896
Week 360.807 ± 14.94939.484 ± 11.3834
Week 485.773 ± 7.881415.260 ± 16.2540
Week 7210.420 ± 1.750115.240 ± 14.3557
Week 9612.84018.433 ± 21.3323
Week 16821.127 ± 14.185419.644 ± 18.6821
Week 19215.10013.080 ± 16.3483
SecondaryPart 1: Patient Global Impression Scales of Symptoms

Patient-reported health status over the past week, by visit, where end of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very Severe. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.

Time frame:
Pre-dose, Week 1, Week 12 (end of treatment)
Reported as:
Mean · Score on a scale
Part 1: Patient Global Impression Scales of Symptoms
Score on a scaleExperimental: ElamipretidePlacebo
Predose1.7 ± 0.651.8 ± 0.83
Week 11.7 ± 0.891.5 ± 1.00
Week 121.4 ± 0.791.6 ± 0.67
SecondaryPart 2: Change From Baseline: Patient Global Impression Scales of Symptoms by Visit

Part 2: Change from Baseline: Patient Global Impression Scales of Symptoms by Visit Patient-reported health status over the past week where Baseline= Part 1 Period 1 Pre-dose, administered at Week 12 for Period 1 and Period 2. Scores range from 0-40 for adolescents and 0-50 for adults. PGI Scale is as follows: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe. Change from baseline: Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192
Reported as:
Mean · score on a scale
Part 2: Change From Baseline: Patient Global Impression Scales of Symptoms by Visit
score on a scalePart 2: OLE: (Sequence AB)Part 2: OLE: (Sequence BA)
End of Part 10.0 ± 0.00-0.4 ± 0.55
Week 12-0.2 ± 1.10-0.6 ± 0.55
Week 24-0.3 ± 0.50-0.4 ± 0.55
Week 36-0.7 ± 1.15-0.6 ± 0.55
Week 48-0.7 ± 1.150.0 ± 0.00
Week 72-0.7 ± 1.15-0.4 ± 0.55
Week 96-0.5 ± 2.12-0.3 ± 0.58
Week 120-0.7 ± 1.15-0.6 ± 0.55
Week 144-1.0 ± 1.41-0.8 ± 0.45
Week 168-0.7 ± 1.15-0.6 ± 0.55
Week 192-2.0-0.5 ± 0.71
SecondaryPart 1: Part 1: Clinician Global Impression

Clinician Global Impression Scale by visit: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Higher score means worse health status, means worse outcome; lower score means better health status, means better outcome. End of treatment means end of Visit 5 (Week 12) for Period 1 and end of Visit 10 (Week 12) for Period 2. Results were pooled for each 12 week period.

Time frame:
Pre-dose to Week 12 (end of treatment)
Reported as:
Mean · Score on a scale
Part 1: Part 1: Clinician Global Impression
Score on a scaleExperimental: ElamipretidePlacebo
Predose1.8 ± 0.451.4 ± 0.51
12 weeks1.6 ± 0.511.6 ± 0.51
SecondaryPart 2: Change From Baseline: CGI Symptom Scale

Change from Baseline: CGI Symptom Scale by visit where Baseline= Part 1 Period 1 Pre-dose. Clinician Global Impression Scale: Clinician-reported overall health status at end of treatment, administered at Week 12 for Period 1 and Period 2. Scores range from 0-6 for both adolescents and adults. PGI Scale is as follows: 1= Very much Better, 2= Moderately Better, 3= A Little Better, 4= No Change, and 5= A Little Worse 6= Very much Worse. Change from baseline: higher score means worse health status, means worse outcome; lower score means better health status, means better outcome.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 72, 96, 120, 144, 168, 192
Reported as:
Mean · score on a scale
Part 2: Change From Baseline: CGI Symptom Scale
score on a scalePart 2: OLE: (Sequence AB)Part 2: OLE: (Sequence BA)
Week 12-0.4 ± 0.550.0 ± 0.00
Week 24-1.3 ± 0.96-0.4 ± 0.55
Week 36-1.3 ± 0.58-0.2 ± 0.84
Week 48-1.3 ± 0.58-0.4 ± 0.55
Week 72-1.3 ± 0.58-0.6 ± 0.55
Week 96-1.0 ± 0.00-0.7 ± 0.58
Week 120-1.7 ± 0.58-1.0 ± 0.71
Week 144-1.3 ± 0.58-0.6 ± 0.55
Week 168-1.3 ± 0.58-0.8 ± 0.84
Week 192-1.0-1.5 ± 0.71

Adverse events

Collected over Part 1: Participants were followed for a total of 28 weeks, they had a treatment period for 12 weeks, a washout period of 4 weeks, then another treatment period of 4 weeks. Part 2 OLE: Participants who agreed to proceed to Part 2 were followed for up to 192 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 2 (OLE): Elamipretide (Sequence AB)0/5 (0%)1/5 (20%)5/5 (100%)
Part 2 (OLE): Elamipretide (Sequence BA)0/5 (0%)4/5 (80%)5/5 (100%)
Part 1: Elamipretide0/6 (0%)0/12 (0%)12/12 (100%)
Part 1: Placebo0/6 (0%)0/12 (0%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventPart 2 (OLE): Elamipretide (Sequence AB)Part 2 (OLE): Elamipretide (Sequence BA)Part 1: ElamipretidePart 1: Placebo
PneumothoraxRespiratory, thoracic and mediastinal disorders0/51/50/120/12
MucositisGeneral disorders0/51/50/120/12
CostochondritisMusculoskeletal and connective tissue disorders0/51/50/120/12
Abscess of Right AxillaInfections and infestations0/51/50/120/12
GastroenteritisInfections and infestations1/50/50/120/12
Most frequent other events
Showing 10 of 122
Most frequent other events
EventPart 2 (OLE): Elamipretide (Sequence AB)Part 2 (OLE): Elamipretide (Sequence BA)Part 1: ElamipretidePart 1: Placebo
Injection site erythemaGeneral disorders3/55/512/123/12
Injection site pruritusGeneral disorders3/55/58/122/12
DizzinessNervous system disorders5/51/51/121/12
Injection site painGeneral disorders3/54/59/124/12
Injection site indurationGeneral disorders2/53/58/122/12
Injection site urticariaGeneral disorders2/50/53/120/12
HeadacheNervous system disorders2/51/51/123/12
Weight decreasedInvestigations0/52/50/120/12
Ear infectionInfections and infestations0/52/50/120/12
Gastroenteritis viralInfections and infestations0/52/50/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental: Elamipretide (Treatment AB)Experimental Placebo (Treatment BA)Total
Part 123.3 ± 9.0715.7 ± 3.3319.5 ± 7.65
PART 2: OLE21.8 ± 9.2316.2 ± 3.4219.0 ± 7.20
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Elamipretide (Treatment AB)Experimental Placebo (Treatment BA)Total
Part 1 — Female000
Part 1 — Male6612
Part 2 (OLE) — Female000
Part 2 (OLE) — Male5510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Elamipretide (Treatment AB)Experimental Placebo (Treatment BA)Total
Part 1 — American Indian or Alaska Native000
Part 1 — Asian000
Part 1 — Native Hawaiian or Other Pacific Islander000
Part 1 — Black or African American000
Part 1 — White6511
Part 1 — More than one race011
Part 1 — Unknown or Not Reported000
Part 2 (OLE) — American Indian or Alaska Native000
Part 2 (OLE) — Asian000
Part 2 (OLE) — Native Hawaiian or Other Pacific Islander000
Part 2 (OLE) — Black or African American000
Part 2 (OLE) — White549
Part 2 (OLE) — More than one race011
Part 2 (OLE) — Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Experimental: Elamipretide (Treatment AB)Experimental Placebo (Treatment BA)Total
United States6612
Body Mass Index
Body Mass Index(kg/m^2)Experimental: Elamipretide (Treatment AB)Experimental Placebo (Treatment BA)Total
Part 118.23 ± 3.67716.88 ± 4.17917.56 ± 3.818
Part 2 OLE18.14 ± 4.10317.54 ± 4.31317.84 ± 3.981
08

Study locations

1 site
  • McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Oct 2018, 15 months.

Results were first posted in Apr 2024, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2017
First posted
Apr 4, 2017
StartActual
Jul 5, 2017
Primary completionActual
Oct 5, 2018
CompletionActual
Oct 11, 2021
Results first posted
Apr 16, 2024
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03098797
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Jul 5, 2017
Primary completion
Oct 5, 2018
Completion
Oct 11, 2021
Results posted
Apr 16, 2024
Last update
Apr 16, 2024

Study contacts

Hilary Vernon, MD, PhD
principal investigator · McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion